Stockscreener 앱 받기
26.68
0.37%
-0.10
시장 영업 전:
26.40
-0.28
-1.05%
Zymeworks Inc. 주식(ZYME)의 최신 뉴스
Pictet Asset Management Holding SA Invests $1.97 Million in Zymeworks Inc. $ZYME - MarketBeat
Kornitzer Capital Management Inc. KS Takes $2.34 Million Position in Zymeworks Inc. $ZYME - MarketBeat
H.C. Wainwright reiterates Zymeworks stock rating on FDA filing By Investing.com - Investing.com India
Zymeworks Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
H.C. Wainwright reiterates Zymeworks stock rating on FDA filing - Investing.com UK
Zymeworks (NASDAQ:ZYME) Raised to Strong-Buy at Truist Financial - MarketBeat
Zymeworks (NASDAQ:ZYME) Hits New 52-Week HighTime to Buy? - MarketBeat
HC Wainwright & Co. Upgrades Zymeworks (ZYME) - MSN
Zymeworks appoints Kristin Stafford as CFO - MSN
Zymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar Ziihera - Yahoo Finance
Zymeworks stock hits 52-week high at $28.50 By Investing.com - Investing.com India
Zymeworks Inc. (NASDAQ:ZYME) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Zymeworks (NASDAQ:ZYME) Hits New 1-Year HighWhat's Next? - MarketBeat
Zymeworks stock hits 52-week high at $28.50 - Investing.com
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026 - wahanariau.com
Stifel reiterates Zymeworks stock rating on ADC data strength - Investing.com UK
Zymeworks reports phase 1 trial results for ovarian cancer drug By Investing.com - Investing.com South Africa
PERCEPTIVE ADVISORS LLC Expands Stake in Zymeworks Inc with Sign - GuruFocus
Zymeworks reports phase 1 trial results for ovarian cancer drug - Investing.com
Zymeworks (ZYME) Broadens ADC Toolkit at AACR 2026 Is Its Oncology Platform Taking Shape? - simplywall.st
Experimental Zymeworks cancer drug shows 61% response in ovarian study - Stock Titan
AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data - BioSpace
Zymeworks Inc stock (US98985W1080): Is its bispecific antibody platform resilient enough for biotech - AD HOC NEWS
A Look At Zymeworks (ZYME) Valuation As AACR 2026 ADC Data Draws Investor Attention - Sahm
Zymeworks presents preclinical data on ADC pipeline at AACR By Investing.com - Investing.com Australia
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform - wahanariau.com
Zymeworks presents preclinical data on ADC pipeline at AACR - Investing.com
Zymeworks Inc. - Via Ritzau
Zymeworks (ZYME) price target increased by 12.53% to 40.88 - MSN
Zymeworks Inc. (ZYME) Stock Analysis: Robust Buy Ratings And Promising Upside Potential - DirectorsTalk Interviews
Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026 - Sahm
How Investors May Respond To Zymeworks (ZYME) Hiring EcoR1 Executives To Lead R&D And Deals - Yahoo Finance
Cancer meeting data show Zymeworks testing targeted drugs for RAS tumors - Stock Titan
Zymeworks Sets May 7 Date to Unveil Q1 2026 Results and Pipeline Update - TipRanks
Perceptive-linked holders report 3.97M shares of Zymeworks (ZYME) - Stock Titan
Zymeworks Inc stock (US98986T1088): Why its biopharma pipeline strategy is suddenly worth a closer l - AD HOC NEWS
Zymeworks Inc. (NYSE:ZYME) Q1 2025 Earnings Call Transcript - MSN
How Investors Are Reacting To Zymeworks (ZYME) Elevating EcoR1 Veterans To Key Executive Roles - simplywall.st
Zymeworks Inc stock (US98986T1088): Why its biopharma pipeline is suddenly worth a closer look - AD HOC NEWS
0.14%
0.48%
자본화:
|
볼륨(24시간):